Allos Therapeutics Inc - Current report filing (8-K)
05 Novembro 2007 - 11:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
November 5, 2007 (November
5, 2007)
ALLOS THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
000-29815
|
54-1655029
|
(State or other
jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
11080
CirclePoint Road, Suite 200
Westminster,
Colorado
|
80020
|
(Address of principal
executive offices)
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
|
|
Not
applicable
|
(Former name or former
address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations
and Financial Condition.
On November 5, 2007,
Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a
press release relating to the Companys financial results for the third quarter
of fiscal year 2007. The press release is attached hereto as
Exhibit 99.1, which is furnished under Item 2.02 of this report and shall
not be deemed to be filed for purposes of Section 18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, regardless of any general
incorporation language in such filing.
Section
9 - Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release titled Allos Therapeutics Reports
Third Quarter 2007 Financial Results, dated November 5, 2007.
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: November 5, 2007
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ David C. Clark
|
|
David C. Clark
|
Its:
|
Vice President, Finance and Treasurer
|
3
EXHIBIT
INDEX
Exhibit
No. Description
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release titled
Allos Therapeutics Reports Third Quarter 2007 Financial Results, dated
November 5, 2007.
|
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics Inc